A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemiaSimon He, Andrew W. Roberts, Mark Hertzberg et al.|Leukemia & lymphoma/Leukemia and lymphoma|2014Cited by 126